Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

CAPS Rating: 3 out of 5

A biopharmaceutical company developing novel therapeutics based on RNA interference, which is a naturally occurring biological pathway within cells for selectively silencing and regulating specific genes.

Recs

3
Player Avatar PDTBiotech (88.96) Submitted: 12/17/2010 8:58:32 AM : Underperform Start Price: $9.90 ALNY Score: -844.93

Alnylam has done an amazing job at keeping RNAi hyped as a legitimate technology, but the jig seems to be nearly up. Deal flow has been declining for a few years, marquis partners are starting to throw in the towel, and anyone who has ever worked with this technology in a lab is wondering how the hell anyone was able to get this far with something that is dirty even in a dish and can't be delivered.

Member Avatar zzlangerhans (99.85) Submitted: 2/18/2011 2:16:11 PM
Recs: 0

Yikes, just saw this when I pulled up the page to record my GBMB sell. Glad I didn't see it when I was still holding, I take your opinions pretty seriously.

Featured Broker Partners


Advertisement